Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kwee Yong

Showing results (31-40 of 187) with videos related to

Pageof 19
Sort By:
Plos One|July 23, 2014
The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surfaceFuiyee Lee, Martha Luevano, Paul Veys, et al.
BMC Cancer|April 18, 2023
"What I wanted to do was build myself back up and prepare": qualitative findings from the PERCEPT trial of prehabilitation during autologous stem cell transplantation in myelomaOrla McCourt, Abigail Fisher, Joanne Land, et al.
Acta Oncologica (Stockholm, Sweden)|February 16, 2023
Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT pilot randomised controlled trialOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
BMJ Open|February 1, 2020
PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myelomaOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
Future Oncology (London, England)|December 14, 2019
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study designPhilippe Moreau, Meletios A Dimopoulos, Kwee Yong, et al.
The Lancet. Oncology|February 3, 2020
Levofloxacin prophylaxis in patients with myeloma - Authors' replyMark T Drayson, Stella Bowcock, Tim Planche, et al.
British Journal of Haematology|June 24, 2023
Functional and psychological impact of minimal residual disease assessment on patients with multiple myelomaNuno Correia, Emma Dowling, Rakesh Popat, et al.
British Journal of Haematology|August 9, 2014
An alternative dosing strategy of lenalidomide for patients with relapsed multiple myelomaRakesh Popat, Iftekhar Khan, Jenny Dickson, et al.
British Journal of Haematology|August 1, 2014
The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myelomaDeepika Kassen, Sally Moore, Laura Percy, et al.
BMJ Open|April 9, 2022
Adaptation of the PERCEPT myeloma prehabilitation trial to virtual delivery: changes in response to the COVID-19 pandemicOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
Pageof 19

Showing results (31-40 of 187) with videos related to

Sort By:
Pageof 19
Plos One|July 23, 2014
The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surfaceFuiyee Lee, Martha Luevano, Paul Veys, et al.
BMC Cancer|April 18, 2023
"What I wanted to do was build myself back up and prepare": qualitative findings from the PERCEPT trial of prehabilitation during autologous stem cell transplantation in myelomaOrla McCourt, Abigail Fisher, Joanne Land, et al.
Acta Oncologica (Stockholm, Sweden)|February 16, 2023
Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT pilot randomised controlled trialOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
BMJ Open|February 1, 2020
PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myelomaOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
Future Oncology (London, England)|December 14, 2019
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study designPhilippe Moreau, Meletios A Dimopoulos, Kwee Yong, et al.
The Lancet. Oncology|February 3, 2020
Levofloxacin prophylaxis in patients with myeloma - Authors' replyMark T Drayson, Stella Bowcock, Tim Planche, et al.
British Journal of Haematology|June 24, 2023
Functional and psychological impact of minimal residual disease assessment on patients with multiple myelomaNuno Correia, Emma Dowling, Rakesh Popat, et al.
British Journal of Haematology|August 9, 2014
An alternative dosing strategy of lenalidomide for patients with relapsed multiple myelomaRakesh Popat, Iftekhar Khan, Jenny Dickson, et al.
British Journal of Haematology|August 1, 2014
The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myelomaDeepika Kassen, Sally Moore, Laura Percy, et al.
BMJ Open|April 9, 2022
Adaptation of the PERCEPT myeloma prehabilitation trial to virtual delivery: changes in response to the COVID-19 pandemicOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
Pageof 19